Q4 EPS Forecast for Halozyme Therapeutics Raised by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Investment analysts at Zacks Research upped their Q4 2025 earnings per share estimates for shares of Halozyme Therapeutics in a report issued on Wednesday, January 28th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $1.77 for the quarter, up from their previous estimate of $1.76. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q2 2026 earnings at $1.49 EPS, Q4 2026 earnings at $1.84 EPS and Q3 2027 earnings at $2.02 EPS.

Several other research firms have also commented on HALO. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. Morgan Stanley decreased their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a report on Monday, October 20th. Finally, Citizens Jmp boosted their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $78.80.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $71.71 on Friday. The company has a market capitalization of $8.43 billion, a PE ratio of 15.10, a P/E/G ratio of 0.32 and a beta of 0.94. The company has a 50-day simple moving average of $68.93 and a two-hundred day simple moving average of $68.36. Halozyme Therapeutics has a one year low of $47.50 and a one year high of $79.50. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. During the same period in the prior year, the business posted $1.27 EPS. The firm’s quarterly revenue was up 22.1% on a year-over-year basis.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently bought and sold shares of the company. Root Financial Partners LLC purchased a new position in Halozyme Therapeutics during the 3rd quarter worth approximately $25,000. Larson Financial Group LLC grew its position in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the period. Richardson Financial Services Inc. grew its holdings in Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 198 shares during the period. Clearstead Advisors LLC increased its position in shares of Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in shares of Halozyme Therapeutics in the second quarter worth about $32,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 16,569 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $68.92, for a total value of $1,141,935.48. Following the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $48,844,913.48. This represents a 2.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 41,398 shares of company stock worth $2,861,352 over the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer‑term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt‑on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell‑side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi‑year gains — useful context for longer‑term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near‑term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near‑term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.